Supporting NuVasive’s commitment to transforming and advancing spine surgery, the Company will showcase its industry-leading innovation through the introduction of new technologies to address the latest advancement in lumbar and cervical spine surgery. Additionally, the Company continues to support surgeon education through numerous education workshops, with demonstrations of its Integrated Global Alignment (iGA™) system, as well as practical clinics highlighting the advantages of minimally-invasive techniques and ongoing surgeon support and adoption.

Advertisement

Pat Miles, President and Chief Operating Officer of NuVasive, commented, “Our latest solutions reinforce NuVasive’s continued commitment to industry-leading innovation that clearly demonstrates the clinical and economic value of our procedurally-integrated offerings for spine. We are laser-focused on providing surgeons and health systems products designed to provide the best possible patient outcomes.”

NuVasive AANS Participation Details

The Company will showcase and have available for demonstrations its new technologies at NuVasive Booth #4627 on the AANS exhibit floor, including:

• AttraX® Putty Biotextured™ Bone Graft: AttraX Putty is a next generation, synthetic biologic product indicated for use as an autograft extender in posterior lateral spine applications. Its unique Biotextured surface technology promotes bone formation and its unique formulation provides excellent handling characteristics.
• Reline® Modular System and Reline Power: Reline Modular (MOD) is designed to improve visualization and access to the intervertebral disc for fusion work in TLIF and PLIF procedures, while providing expanded decortication and superior distraction. This modular-based, pedicle screw system includes unique modular tulip designs that provide for versatile implant options. Reline Power expedites screw placement with its integrated power delivery system, ergonomically designed for surgeons.
• MAS® TLIF 2: MAS TLIF 2 is the next generation of NuVasive’s minimally-invasive, pedicle-based approach to provide efficient, reproducible and step-by-step technique for TLIF procedures. This updated system includes a re-designed retractor for improved visibility and functionality, an innovative screw shank attachment that is simple and secure, as well as advanced interbody and graft delivery solutions.
• Monolith™ Corpectomy System: Monolith is a fully modular, imaging-friendly PEEK implant indicated for use T1-L5 with supplemental fixation. The system features multiple core, endcap and angulation options, which provide surgeons versatility in the OR.

NuVasive’s exhibit booth will include additional products and procedures, featuring an enhanced interactive experience highlighting iGA’s proprietary, procedurally-integrated, digital platform of specialized products designed to help surgeons achieve more precise spinal column alignment. Additionally, the booth will highlight the recently added MAGnetic External Control, or MAGEC®, early-onset scoliosis spinal bracing and distraction system.

NuVasive will host a series of workshops and practical clinics at AANS 2016. Visit the Company’s website for a downloadable list.

About NuVasive

NuVasive is a global medical device company focused on transforming spine surgery by empowering surgeons with technology to approach procedures in the least disruptive way possible and restore the vitality of life for those that suffer from debilitating spinal conditions. Through its minimally invasive, procedurally-integrated solutions, the Company is expanding the boundaries of modern healthcare with technologies and surgeon training designed to provide reproducible and clinically-proven surgical outcomes that are redefining the success factors of spine surgery like never before. Addressing a variety of pathologies up and down the spine, from complex spinal deformity to degenerative spinal conditions, NuVasive’s highly differentiated solutions include access instruments, implantable hardware and increasingly expert software systems like its game-changing iGA™ surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. NuVasive believes its integrated approach and expertise can fundamentally evolve spine care by delivering improved patient experiences, and better economics healthcare systems. With $811 million in revenues as of the end of 2015, NuVasive has an approximate 1,600 person workforce in more than 40 countries around the world. For more information on the Company, please visit www.nuvasive.com.

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Contact Information

Media Contact:
Michael Farrington
NuVasive, Inc.
858-909-1940
media@nuvasive.com

Investor Contact:
Stacy Roughan
NuVasive, Inc.
858-909-1812
investorrelations@nuvasive.com